Biotech Startups

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung. Its lead-212-based programs, such as ADVC001 for metastatic prostate cancer, are in clinical development.

5 investors

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism. The company's lead candidate, AV078, is a CNS-penetrant mTORC1 inhibitor in development for tuberous sclerosis complex refractory epilepsy.

5 investors

Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases. The company focuses on advancing transformative treatments in areas including oncology, rare genetic diseases, and cell therapies.

5 investors

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease. The company serves eye care professionals and patients in the global ophthalmic pharmaceutical market.

5 investors

Owkin develops AI Scientist, an autonomous AI system that uses biological large language models and multimodal patient data to accelerate drug discovery for pharmaceutical and biotech companies. The company aims to automate early-stage R&D and compress decades of discovery timelines into years.

5 investors

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing. It focuses on treating the underlying causes of hearing loss, including genetic hearing loss.

5 investors

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration. The company focuses on patients with neurodegenerative conditions and applies genetics, neuroscience, and immunology to advance new treatments.

5 investors

Nobell Foods produces plant-based dairy cheese made from soybean plants engineered to grow casein protein, working with Midwest farmers. The company targets consumers seeking sustainable cheese alternatives that match the taste and melt characteristics of traditional dairy cheese.

5 investors

Amai Proteins uses its Pro3 platform, combining AI computational protein design with precision fermentation, to develop designer sweet proteins that replace 40-70% of added sugar in food and beverage products without altering taste. It targets the mass food and beverage industry with applications across soft drinks, dairy, sauces, snacks, and functional foods.

5 investors

Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease. The company focuses on pharmaceutical development and clinical research in the cardiovascular health sector.

5 investors

Amatera develops crop genetics using cell culture, high-throughput automation, and machine learning to accelerate breeding of perennial crops such as coffee, grapevine, and bananas. It builds its own climate-resistant and disease-resistant varieties and partners with seed companies, agrifood firms, and research institutes to apply its CellTera technology for faster trait discovery.

5 investors

Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.

5 investors

5 investors

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders. It targets diseases with significant unmet medical needs.

5 investors

AnaCardio is a clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, including its GOAL-HF1 program for patients with Heart Failure and Reduced Ejection Fraction (HFrEF).

5 investors

Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods. It serves scientists in gene and cell therapies, antibody discovery, CDMOs, and agrigenomics.

5 investors

AOI Biosciences is a Japanese biotech company focused on infectious diseases and autoimmune disorders, combining data analysis technology with proprietary bio-technology. It operates diagnostic testing, drug discovery, and drug discovery support businesses.

5 investors

Aphea.Bio develops biological crop protection products and biostimulants, including bioinsecticides targeting crop pests. The company works with agricultural partners to develop sustainable alternatives to conventional agrochemicals.

5 investors

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

5 investors

5 investors

Arda engineers plastic-free materials from spent grain sourced from brewers and distillers, using protein hierarchies and nontoxic chemistry. The company produces performance materials for fashion, beauty, automotive, and other industries while enabling circular supply chains.

5 investors

Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.

5 investors

Asimov develops a computer-aided design platform for genetic engineering, enabling designers to program living cells by applying abstraction, standardization, and modeling to biology. The company serves genetic engineers and biotechnology researchers building engineered biological systems.

5 investors

Ataraxis develops AI foundation models that analyze multi-modal patient data, including pathology slide images, to assess cancer aggressiveness and predict recurrence risk and treatment response. Its first product, Ataraxis Breast, provides clinically validated prognostic and predictive tools for breast cancer patients and their physicians.

5 investors